Author, year | Country | Study period | Study design | Follow-up | Comparison | Size | Age, mean ± SD | Gender, male, n (%) |
---|---|---|---|---|---|---|---|---|
Ke, L., 2021 [48] | China | 2018–2019 | Prospective, single-center, randomized controlled trial | 90 Days | ED | 15 | 38 ± 18 | 11 (73.3%) |
DD | 15 | 40 ± 16 | 9 (60%) | |||||
Boxhoorn, L.,2021 [47] | Netherlands | 2015–2019 | Prospective, multicenter, randomized, controlled superiority trial | 3 Months/6 months | ED | 55 | 60 ± 14 | 32 (58%) |
DD | 49 | 59 ± 11 | 32 (65%) | |||||
Bang, J., 2019 [46] | The USA | 2014–2017 | Prospective, single-center, randomized trial | 6 Weeks/6 months | ES | 32 | 52.9 ± 14.2 | 21 (65.6%) |
EEU | 34 | 55.6 ± 14.2 | 22 (64.7%) | |||||
van Brunschot, 2018 [45] | Netherlands | 2011–2015 | Prospective, multicenter randomized, superiority trial | 3 Months/6 months | DEU | 51 | 63 ± 14 | 34 (67%) |
DSU | 47 | 60 ± 11 | 29 (62%) | |||||
Bakker, 2012 [44] | Netherlands | 2008–2010 | Prospective, randomized controlled assessor-blinded clinical trial | 3 Months/6 months | DE | 10 | 60 ± 22 | 8 (80%) |
DS | 10 | 60 ± 19 | 6 (60%) | |||||
van Santvoort, 2010 [43] | Netherlands | 2005–2008 | Prospective, multicenter randomized controlled superiority trial | 3 Months/6 months | DS | 45 | 57.4 ± 2.0 | 33 (73%) |
DSU | 43 | 57.6 ± 2.1 | 31 (72%) | |||||
Litvin A, 2010 [42] | Belarus | 2004–2008 | Prospective, multicenter randomized trial | NR | DSU | 37 | NR | NR |
ES | 35 | NR | NR | |||||
Mier, J., 1997 [41] | Mexico | 1990–1993 | Prospective, single-center, randomized trial | NR | ES | 25 | 42 ± 16 | 15 (60%) |
DS | 11 | 42 ± 12 | 7 (63.6%) | |||||
Schröder, T, 1991 [40] | Finland | 1984–1988 | Prospective, single-center, randomized trial | NR | ES | 11 | 40.5 ± 7.5 | 10 (90.9%) |
ED | 10 | 35.7 ± 6.8 | 9 (90%) | |||||
Kivilaakso, E, 1984 [39] | Finland | 1997–1982 | Prospective, single-center, randomized trial | NR | ES | 18 | 38.4 ± 10.2 | 16 (88.9%) |
ED | 17 | 39.7 ± 10 | 14 (82.4%) |